CD274 and neoplasm: As part of the clinical trial, a FoundationONE CDx test was performed on tissue biopsy: molecular analyses confirmed the MSI-high status and a high tumour mutational burden (13 Muts/Mb); PD-L1 and PD-L2 genes were also found to be amplified.